Form 4 for PRLD Prelude Therapeutics Inc
Accepted 2023-07-06 00:00:00 ET · period of report 2023-07-04 · accession 0001209191-23-041553 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-07-06 | 2023-07-04 | PRLD | Huang Jane | Pres, CMO | M - OptEx | — | +9,375 | 33.6K | +39% | — |
| D | 2023-07-06 | 2023-07-04 | PRLD | Huang Jane | Pres, CMO | F - Tax | $4.65 | -3,242 | 30.4K | -10% | -$15.1K |
| D | 2023-07-06 | 2023-07-04 | PRLD | Huang Jane | Pres, CMO | M - OptEx | $0.00 | -9,375 | 103.1K | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-07-04 | M | A | 9,375 | — | 33,595 | D | — | — | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. |
| 2 | Common | Common Stock | 2023-07-04 | F | D | 3,242 | $4.65 | 30,353 | D | — | — | (F2) Represents shares withheld by the Issuer to satisfy the tax withholding obligation in connection with the vesting of RSUs. |
| 3 | Derivative | Restricted Stock Unit | 2023-07-04 | M | D | 9,375 | $0.00 | 103,125 | D | — · — to — | 9,375 Common Stock | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. (F3) The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date. |